AliveCor launches $0 Medicare health program

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

AliveCor’s new KardiaACCESS program offers Medicare beneficiaries free, clinician-guided cardio-kidney-metabolic care.

More than 70% of Americans between 60 and 79 are living with cardiovascular disease, according to the American Heart Association. The Centers for Disease Control and Prevention (CDC) puts the broader number even higher – three in four US adults have at least one chronic condition, usually a few that feed off each other: high blood pressure straining the kidneys, kidney trouble straining the heart, and so on.

AliveCor, the company that makes the Kardia personal ECG devices, is betting that treating all of that as one connected system, rather than three separate diagnoses handled by three separate specialists, actually works better. It’s launching a Medicare-backed program to test that bet at scale [1].

Free, for a decade, under a federal model

The program is called KardiaACCESS, and it runs under a CMS Innovation Center initiative called the ACCESS Model, short for Advancing Chronic Care with Effective, Scalable Solutions. It’s a 10-year commitment. For eligible Original Medicare Part B beneficiaries, it costs nothing: no copays, no deductibles, nothing hidden in the fine print. It’s already live in 48 states, with Arkansas and South Carolina expected to join soon.

There are two tracks. One, called eCKM, is aimed at people with high blood pressure or cholesterol, prediabetes, or who are overweight, catching risk before it turns into disease. The other, CKM, is for people already managing Type 2 diabetes, chronic kidney disease or established heart disease. Both tracks come with connected devices, lifestyle coaching, virtual visits, and access to the Kardia app, coordinated by a clinical partner called Kardia Medical Group.

“We’ve been helping patients manage heart health conditions for over a decade,” said Priya Abani, CEO of AliveCor. “We know the center of chronic disease management often starts at the heart, and we are uniquely positioned to connect the dots across cardio-kidney-metabolic health. With KardiaACCESS, we provide active clinical guidance and medical-grade tools to help people manage their blood pressure, diabetes, lipids and weight, empowering them to improve their real health numbers, reduce risks and protect their hearts from home.”

A ten-minute checkup twice a year, which is about what a lot of Medicare patients actually get, isn’t much time to catch a slow creep in blood pressure or blood sugar before it turns into something bigger. That’s really the gap this program is trying to close. Not with more appointments necessarily, but with something checking in between them, and an actual clinical team behind it rather than just an app throwing numbers back at someone with no context.

Why treat it all as one system

Doctors studying aging have mostly stopped treating heart, kidney and metabolic disease as separate problems, at least the ones paying close attention. The three influence each other so consistently that a lot of clinicians now just call it one syndrome, cardio-kidney-metabolic, or CKM. Managing one piece in isolation tends to work worse than managing the whole system together, and that’s more or less the logic AliveCor built this program around.

AliveCor isn’t new to any of this. The company pioneered personal ECG technology and has recorded more than 400 million ECGs from over 6.4 million patients in more than 40 countries. Its devices are cleared to detect 39 distinct cardiac conditions, heart attacks and ischemia included, backed by more than 250 peer-reviewed publications. That track record is likely a big reason CMS chose to build a national model around the company in the first place, rather than starting from scratch with something unproven.

Whether a ten-year federal program actually moves outcomes at the scale CMS is hoping for is genuinely unclear this early. But removing cost as a barrier, for the exact population facing the highest cardiovascular risk, is at least a real attempt at catching problems before they turn into hospital stays, instead of just paying for the hospital stay afterward.

[1] https://alivecor.com/press/press_release/kardia-access-medicare-covered-program

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Alzheimer’s drug market faces a $14.7bn future

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE